-
‣About TrovaGene
TrovaGene is focused on the development of molecular diagnostic tests using its proprietary methods for transrenal DNA (Tr-DNA) and RNA (Tr-RNA) detection.
TrovaGene, Inc. (TROV.PK), a publicly traded company based in San Diego, Calif., is dedicated to the development and commercialization of transrenal molecular in-vitro diagnostic products. Formerly known as Xenomics, Inc., TrovaGene (from the Italian root word meaning “to find”) is initially targeting medical conditions in which the standard of care requires samples that are difficult, painful, or dangerous to obtain and analyze as well as conditions for which no diagnostic tests currently exist. These targets include tests for the detection and monitoring of cancers and infectious diseases, prenatal genetic testing, and the monitoring of organ/cell transplants.
The company’s founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.
TrovaGene has a dominant patent position as it relates to transrenal molecular testing. It has issued U.S. and European patents that cover any and all testing for molecular targets that pass through the kidney. In addition to these core patents it has numerous patent applications pending in the areas of cancer, infectious diseases, transplantation, prenatal and genetic testing. This patent position rivals the importance of the Roche PCR and Gen-Probe ribosomal RNA patents in the molecular diagnostic field.
TROV.PK
